Invenra and Orion Corporation, a globally operating pharmaceutical company, announced recently that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform. “This collaboration highlights…
Invenra announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designations (ODD) to its innovative bispecific antibody, INV724, developed for…
Invenra is partnering with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients, the company announced today. According to a release, the…
Invenra has expanded its discovery and licensing collaboration with Exelixis to include an additional 20 oncology targets, the company announced today. According to a release, the collaboration builds on the…
Invenra announced today that it is extending its collaboration with California-based biotech company Exelixis that began in May 2018. According to a release, Exelixis, which focuses on oncology, will continue to use…
Venture Investors announced recently that it closed its $75 million fund called Venture Investors Health Fund 6 Limited Partnership. According to a release, the fund has made four investments, including…
Invenra and the Wisconsin Alumni Research Foundation have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, the company announced recently. “This…
Invenra will collaborate with Merck, a pharmaceutical company, to discover fully human therapeutic antibodies against an unnamed target of interest to Merck, the company announced recently. “We are excited to…
Invenra has teamed up with Australian biomedical research and development center QIMR Berghofer Medical Research Institute to identify and characterize a panel of fully human therapeutic monoclonal antibodies against a novel…
Invenra announced last week that is has teamed up with UK-based biotech company Oxford BioTherapeutics (OBT) to identify and characterize a panel of fully human therapeutic monoclonal antibodies (mAbs) against…
